Clinical Trial Update: Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study [Phase 2]

View source ↗

Summary

A single-arm Phase II trial evaluating neoadjuvant durvalumab, anlotinib, and chemotherapy followed by curative resection in stage III non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Chemotherapy (chemotherapy)
• Durvalumab (durvalumab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN